Trials / Terminated
TerminatedNCT01625455
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Vanderbilt University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this randomized, double-blinded, placebo-controlled study is to test the hypothesis that administration of aprepitant will decrease the severity of pruritus in patients with Sèzary Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aprepitant | Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days. |
| DRUG | Placebo | Placebo will be given orally for a total of 7 days. |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2015-07-01
- Completion
- 2016-07-01
- First posted
- 2012-06-21
- Last updated
- 2017-05-10
- Results posted
- 2017-05-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01625455. Inclusion in this directory is not an endorsement.